Offering mifepristone as an abortion option

Helen C. Pymar, Mitchell D Creinin

Research output: Contribution to journalArticle

Abstract

While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalContemporary Ob-Gyn
Volume46
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Mifepristone
Unwanted Pregnancies
Family Planning Services
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Offering mifepristone as an abortion option. / Pymar, Helen C.; Creinin, Mitchell D.

In: Contemporary Ob-Gyn, Vol. 46, No. 2, 2001, p. 113-119.

Research output: Contribution to journalArticle

Pymar, Helen C. ; Creinin, Mitchell D. / Offering mifepristone as an abortion option. In: Contemporary Ob-Gyn. 2001 ; Vol. 46, No. 2. pp. 113-119.
@article{2379289f55ca40b2820fd340bc4cd72b,
title = "Offering mifepristone as an abortion option",
abstract = "While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.",
author = "Pymar, {Helen C.} and Creinin, {Mitchell D}",
year = "2001",
language = "English (US)",
volume = "46",
pages = "113--119",
journal = "Contemporary Ob/Gyn",
issn = "0090-3159",
publisher = "Advanstar Communications",
number = "2",

}

TY - JOUR

T1 - Offering mifepristone as an abortion option

AU - Pymar, Helen C.

AU - Creinin, Mitchell D

PY - 2001

Y1 - 2001

N2 - While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.

AB - While family planning clinics are hailing the FDA's recent approval of mifepristone (RU-486) as a noninvasive way to terminate an unwanted pregnancy, ob/gyns who decide to administer the drug still need to familiarize themselves with the research on its advantages and disadvantages.

UR - http://www.scopus.com/inward/record.url?scp=24044449955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044449955&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:24044449955

VL - 46

SP - 113

EP - 119

JO - Contemporary Ob/Gyn

JF - Contemporary Ob/Gyn

SN - 0090-3159

IS - 2

ER -